English

Black Diamond Therapeutics, Inc.

EDGAR

BDTX Quarterly report (10-Q) · filed 2026-08-05

37 filing records in this dataset, filed from 2020-01-03 to 2026-08-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2020 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-15.8 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -52146000 USD Source
Operating Cash Flow: -36372000 USD Source

Free cash flow

-15.9 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -52146000 USD Source
Operating Cash Flow: -36372000 USD Source
Capital Expenditure: 142000 USD Source
Capital Expenditure: 33000 USD Source

Cash and cash equivalents: 19.2 million USD 2026-06-30 Source
Exact value

19194000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 57.4 million shares 2026-06-30 Source
Exact value

57446349 shares

Reported share-count change

0.98% · 559 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

56886939 shares · 2025-06-30· Source
57446349 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2020-01-01 – 2020-12-31

Exact inputs and evidence

Revenue: 0 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 0 USD · 2020-04-01 – 2020-06-30 Source
Revenue: 0 USD · 2020-07-01 – 2020-09-30 Source
Revenue: 0 USD · 2020-10-01 – 2020-12-31 Source

Net income

-42.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -8498000 USD · 2025-07-01 – 2025-09-30 Source
Net income: 22367000 USD · 2025-01-01 – 2025-12-31 Source
Net income: 37483000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -9036000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -9905000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-32.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 36401000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 44251000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 29614000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 36401000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10232000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -18200000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -10232000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2020-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2024-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 92.04 million

Prior period

−USD 69.68 million

2024-01-01 – 2024-12-31
Current period

USD 22.37 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

22367000 − -69676000 = 92043000 USD

-69676000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
22367000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Black Diamond Therapeutics, Inc. · 2025-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Year-over-year change in Net income: 92043000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 22367000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1585714 Filing: 000170154126000009 Input fundies:NetIncome: -69676000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1586570 Filing: 000170154126000009
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 91.92 million

Prior period

−USD 62.3 million

2024-01-01 – 2024-12-31
Current period

USD 29.61 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

29614000 − -62303000 = 91917000 USD

-62303000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
29614000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Black Diamond Therapeutics, Inc. · 2025-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Year-over-year change in Operating cash flow: 91917000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 29614000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1166936 Filing: 000170154126000009 Input fundies:OperatingCashFlow: -62303000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1167587 Filing: 000170154126000009
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 0
Operating costs Derived USD 69.57 million
Operating income −USD 69.57 million
Tax, interest and other Derived −USD 2.32 million
Net income −USD 67.25 million

Cash

Operating cash flow −USD 52.15 million
Capital expenditure USD 142,000
Free cash flow Derived −USD 52.29 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	8904000 Derived	-8904000	27000 Derived	-8931000	-8530000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -8904000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -8931000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -8454000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 76000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	29332000 Derived	-29332000	5926000 Derived	-35258000	-24695000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -29332000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -35258000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -24674000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 21000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	69570000 Derived	-69570000	-2316000 Derived	-67254000	-52288000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -69570000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -67254000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -52146000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 142000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2020

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20182018-12-31	Revenue	Revenue: 0 Open source
20192019-12-31	Revenue	Revenue: 0 Open source
20202020-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	Not reported	Operating Income: -8904000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -29332000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -69570000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -8931000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -35258000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -67254000 Open source Revenue: 0 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -8454000 Open source Capital Expenditure: 76000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -24674000 Open source Capital Expenditure: 21000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -52146000 Open source Capital Expenditure: 142000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -52.1M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-8454000	Operating Cash Flow: -8454000 Open source
20192019-12-31	Operating cash flow	-24674000	Operating Cash Flow: -24674000 Open source
20202020-12-31	Operating cash flow	-52146000	Operating Cash Flow: -52146000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -52.3M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-8530000	Operating Cash Flow: -8454000 Open source Capital Expenditure: 76000 Open source
20192019-12-31	Free cash flow	-24695000	Operating Cash Flow: -24674000 Open source Capital Expenditure: 21000 Open source
20202020-12-31	Free cash flow	-52288000	Operating Cash Flow: -52146000 Open source Capital Expenditure: 142000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.6% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	12.7%	Total Liabilities: 6598000 Open source Total Assets: 51826000 Open source
20192019-12-31	Liabilities / assets	3.1%	Total Liabilities: 4879000 Open source Total Assets: 158295000 Open source
20202020-12-31	Liabilities / assets	6.6%	Total Liabilities: 21912000 Open source Total Assets: 329670000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

22.48× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	20.07×	Current Assets: 51684000 Open source Current Liabilities: 2575000 Open source
20192019-12-31	Current assets / current liabilities	32.02×	Current Assets: 155714000 Open source Current Liabilities: 4863000 Open source
20202020-12-31	Current assets / current liabilities	22.48×	Current Assets: 319554000 Open source Current Liabilities: 14218000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 8.93 million Exact value Exact value: -8931000 USD 2018-01-01 – 2018-12-31: -8931000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2018-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -8931000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8931000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000009/bdtx-20191231.htm#2239630 Filing: 000170154120000009 The citation records this snapshot. The page link may show a newer release later.	−USD 8.45 million Exact value Exact value: -8454000 USD 2018-01-01 – 2018-12-31: -8454000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2018-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -8454000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8454000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000009/bdtx-20191231.htm#1332930 Filing: 000170154120000009 The citation records this snapshot. The page link may show a newer release later.	USD 76,000 Exact value Exact value: 76000 USD 2018-01-01 – 2018-12-31: 76000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2018-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 76000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 76000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000009/bdtx-20191231.htm#1338252 Filing: 000170154120000009 The citation records this snapshot. The page link may show a newer release later.	−USD 8.53 million Calculation and evidence -8454000 − 76000 USD Exact free cash flow: -8530000 USD 2018-01-01 – 2018-12-31: -8454000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 76000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2018-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -8530000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8454000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000009/bdtx-20191231.htm#1332930 Filing: 000170154120000009 Input fundies:CapitalExpenditure: 76000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154120000009/bdtx-20191231.htm#1338252 Filing: 000170154120000009 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 35.26 million Exact value Exact value: -35258000 USD 2019-01-01 – 2019-12-31: -35258000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2019-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -35258000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35258000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000018/bdtx-20201231.htm#1972943 Filing: 000170154121000018 The citation records this snapshot. The page link may show a newer release later.	−USD 24.67 million Exact value Exact value: -24674000 USD 2019-01-01 – 2019-12-31: -24674000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2019-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -24674000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24674000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000018/bdtx-20201231.htm#1248970 Filing: 000170154121000018 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2019-01-01 – 2019-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2019-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000018/bdtx-20201231.htm#1251962 Filing: 000170154121000018 The citation records this snapshot. The page link may show a newer release later.	−USD 24.7 million Calculation and evidence -24674000 − 21000 USD Exact free cash flow: -24695000 USD 2019-01-01 – 2019-12-31: -24674000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2019-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -24695000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24674000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000018/bdtx-20201231.htm#1248970 Filing: 000170154121000018 Input fundies:CapitalExpenditure: 21000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000018/bdtx-20201231.htm#1251962 Filing: 000170154121000018 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 67.25 million Exact value Exact value: -67254000 USD 2020-01-01 – 2020-12-31: -67254000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2020-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -67254000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -67254000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000007/bdtx-20211231.htm#1824567 Filing: 000170154122000007 The citation records this snapshot. The page link may show a newer release later.	−USD 52.15 million Exact value Exact value: -52146000 USD 2020-01-01 – 2020-12-31: -52146000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2020-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -52146000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52146000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000007/bdtx-20211231.htm#1274066 Filing: 000170154122000007 The citation records this snapshot. The page link may show a newer release later.	USD 142,000 Exact value Exact value: 142000 USD 2020-01-01 – 2020-12-31: 142000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2020-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 142000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 142000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000007/bdtx-20211231.htm#1277101 Filing: 000170154122000007 The citation records this snapshot. The page link may show a newer release later.	−USD 52.29 million Calculation and evidence -52146000 − 142000 USD Exact free cash flow: -52288000 USD 2020-01-01 – 2020-12-31: -52146000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 142000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2020-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -52288000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52146000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000007/bdtx-20211231.htm#1274066 Filing: 000170154122000007 Input fundies:CapitalExpenditure: 142000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000007/bdtx-20211231.htm#1277101 Filing: 000170154122000007 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 125.6 million Exact value Exact value: -125596000 USD 2021-01-01 – 2021-12-31: -125596000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2021-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -125596000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -125596000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000020/bdtx-20221231.htm#1850806 Filing: 000170154123000020 The citation records this snapshot. The page link may show a newer release later.	−USD 100.15 million Exact value Exact value: -100148000 USD 2021-01-01 – 2021-12-31: -100148000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2021-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -100148000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -100148000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000020/bdtx-20221231.htm#1287191 Filing: 000170154123000020 The citation records this snapshot. The page link may show a newer release later.	USD 2.71 million Exact value Exact value: 2710000 USD 2021-01-01 – 2021-12-31: 2710000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2021-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 2710000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2710000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000020/bdtx-20221231.htm#1290196 Filing: 000170154123000020 The citation records this snapshot. The page link may show a newer release later.	−USD 102.86 million Calculation and evidence -100148000 − 2710000 USD Exact free cash flow: -102858000 USD 2021-01-01 – 2021-12-31: -100148000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2710000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2021-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -102858000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -100148000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000020/bdtx-20221231.htm#1287191 Filing: 000170154123000020 Input fundies:CapitalExpenditure: 2710000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000020/bdtx-20221231.htm#1290196 Filing: 000170154123000020 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 91.17 million Exact value Exact value: -91169000 USD 2022-01-01 – 2022-12-31: -91169000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2022-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -91169000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91169000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000011/bdtx-20231231.htm#1594068 Filing: 000170154124000011 The citation records this snapshot. The page link may show a newer release later.	−USD 85.08 million Exact value Exact value: -85082000 USD 2022-01-01 – 2022-12-31: -85082000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2022-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -85082000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -85082000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000011/bdtx-20231231.htm#1181893 Filing: 000170154124000011 The citation records this snapshot. The page link may show a newer release later.	USD 192,000 Exact value Exact value: 192000 USD 2022-01-01 – 2022-12-31: 192000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2022-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 192000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 192000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000011/bdtx-20231231.htm#1184086 Filing: 000170154124000011 The citation records this snapshot. The page link may show a newer release later.	−USD 85.27 million Calculation and evidence -85082000 − 192000 USD Exact free cash flow: -85274000 USD 2022-01-01 – 2022-12-31: -85082000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 192000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2022-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -85274000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -85082000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000011/bdtx-20231231.htm#1181893 Filing: 000170154124000011 Input fundies:CapitalExpenditure: 192000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000011/bdtx-20231231.htm#1184086 Filing: 000170154124000011 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 82.44 million Exact value Exact value: -82442000 USD 2023-01-01 – 2023-12-31: -82442000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2023-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -82442000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -82442000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1585254 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.	−USD 66.72 million Exact value Exact value: -66717000 USD 2023-01-01 – 2023-12-31: -66717000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2023-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -66717000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66717000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1180496 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.	USD 33,000 Exact value Exact value: 33000 USD 2023-01-01 – 2023-12-31: 33000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2023-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 33000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 33000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1182722 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.	−USD 66.75 million Calculation and evidence -66717000 − 33000 USD Exact free cash flow: -66750000 USD 2023-01-01 – 2023-12-31: -66717000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 33000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2023-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -66750000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66717000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1180496 Filing: 000170154125000016 Input fundies:CapitalExpenditure: 33000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1182722 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 69.68 million Exact value Exact value: -69676000 USD 2024-01-01 – 2024-12-31: -69676000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2024-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: -69676000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -69676000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1586570 Filing: 000170154126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 62.3 million Exact value Exact value: -62303000 USD 2024-01-01 – 2024-12-31: -62303000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2024-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: -62303000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -62303000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1167587 Filing: 000170154126000009 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Black Diamond Therapeutics, Inc. · 2024-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1182125 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.	−USD 62.3 million Calculation and evidence -62303000 − 0 USD Exact free cash flow: -62303000 USD 2024-01-01 – 2024-12-31: -62303000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Black Diamond Therapeutics, Inc. · 2024-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Free cash flow: -62303000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -62303000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1167587 Filing: 000170154126000009 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000016/bdtx-20241231.htm#1182125 Filing: 000170154125000016 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 22.37 million Exact value Exact value: 22367000 USD 2025-01-01 – 2025-12-31: 22367000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Black Diamond Therapeutics, Inc. · 2025-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Net Income: 22367000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 22367000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1585714 Filing: 000170154126000009 The citation records this snapshot. The page link may show a newer release later.	USD 29.61 million Exact value Exact value: 29614000 USD 2025-01-01 – 2025-12-31: 29614000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Black Diamond Therapeutics, Inc. · 2025-12-31 Black Diamond Therapeutics, Inc. (edgar:1701541) Operating Cash Flow: 29614000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1701541/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 29614000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/bdtx-20251231.htm#1166936 Filing: 000170154126000009 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

37 filings · 1,600 latest values · 1,600 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001701541, 1701541, BDTX, edgar:1701541

Also known as Aset Therapeutics, Inc., BLACK DIAMOND THERAPEUTICS, INC., Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation